First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors

Cancer

Volumn 124, Issue 2, 2018, Pages 315-324

  Bédard, Philippe L ^a   Davies, Michael A ^b   Kopetz, Scott ^b   Juric, Dejan ^c   Shapiro, Geoffrey I ^d   Luke, Jason J ^e   Spreafico, Anna ^a   Wu, Bin ^f,h   Castell, Christelle ^g   Gomez, Corinne ^g   Cartot Cotton, Sylvaine ^g   Mazuir, Florent ^g   Dubar, Michel ^g   Micallef, Sandrine ^g   Demers, Brigitte ^g   Flaherty, Keith T ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f Sanofi ^*  (United States)

^g SANOFI   (France)

^h AGIOS PHARMACEUTICALS   (United States)

Author keywords

advanced solid tumor; pharmacodynamics; pharmacokinetics; phosphoinositide 3 kinase (PI3K); SAR260301

Indexed keywords

ANTINEOPLASTIC AGENT; SAR 260301; UNCLASSIFIED DRUG; 2-(2-(2-METHYL-2,3-DIHYDROINDOL-1-YL)-2-OXOETHYL)-6-MORPHOLIN-4-YL-3H-PYRIMIDIN-4-ONE; INDOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PYRIMIDINONE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BAYES THEOREM; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; COUGHING; DEATH; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; IC90; LOSS OF APPETITE; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SOLID MALIGNANT NEOPLASM; THROMBOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ANTAGONISTS AND INHIBITORS; MIDDLE AGED; NEOPLASM;

ADULT; AGED; BAYES THEOREM; FEMALE; HUMANS; INDOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIMIDINONES;

EID: 85040239288     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.31044     Document Type: Article

References (22)

1. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627-644.
2. Shapiro GI, Rodon J, Bedell C, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2014;20:233-245.
3. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28:1075-1083.
4. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011;11:289-301.
5. Wee S, Wiederschain D, Maira SM, et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A. 2008;105:13057-13062.
6. Jia S, Liu Z, Zhang S, et al. Essential roles of PIK-p110β in cell growth, metabolism and tumorigenesis. Nature. 2008;454:776-779.
7. Certal V, Carry JC, Halley F, et al. Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers. J Med Chem. 2014;57:903-920.
8. Schmit F, Utermark T, Zhang S, et al. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A. 2014;111:6395-6400.
9. Bonnevaux H, Lemaitre O, Vincent L, et al. Concomitant inhibition of PI3Kβ and BRAF or MEK in PTEN-deficient/BRAF-mutant melanoma treatment: preclinical assessment of SAR260301 oral PI3Kβ-selective inhibitor. Mol Cancer Ther. 2016;15:1460-1471.
10. Gratacap MP, Guillermet-Guibert J, Martin V, et al. Regulation and roles of PI3Kβ, a major actor in platelet signaling and functions. Adv Enzyme Regul. 2011;51:106-116.
11. Bowers RK, Marder P, Green LJ, Horn CL, Faber AL, Thomas JE. A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy. Mol Cancer Ther. 2007;6:2600-2607.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
13. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Bethesda, MD: National Cancer Institute; 2010.
14. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med. 2008;27:2420-2439.
15. Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics [serial online]. J Hematol Oncol. 2013;6:88.
16. Markman B, Tabernero J, Krop I, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol. 2012;23:2399-2408.
17. Bendell C, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30:282-290.
18. Arkenau HT, Fields Jones S, Kurkjian C, et al. The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors [abstract]. J Clin Oncol. 2012;30(15 suppl):3097.
19. Wagner AJ, Bendell JC, Dolly S, et al. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors [abstract]. J Clin Oncol. 2011;29(15 suppl):3020.
20. Hong DS, Bowles DW, Falchook GS, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:4173-4182.
21. Papadopoulos KP, Egile C, Ruiz-Soto R, et al. Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. Leuk Lymphoma. 2015;56:1763-1770.
22. Arkenau HT, Mateo J, Lemech CR, et al. A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors [abstract]. J Clin Oncol. 2014;32(15 suppl):2514.